Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) has been given a consensus rating of “Hold” by the twenty-five research firms that are covering the firm, MarketBeat reports. Three investment analysts have rated the stock with a sell recommendation, ten have given a hold recommendation, ten have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among brokers that have covered the stock in the last year is $136.04.

Several equities research analysts recently weighed in on the stock. Laidlaw raised shares of Intercept Pharmaceuticals from a “hold” rating to a “buy” rating and set a $90.00 price objective for the company in a research report on Wednesday. Wedbush reaffirmed an “outperform” rating and set a $253.00 price objective on shares of Intercept Pharmaceuticals in a research report on Friday, August 25th. Royal Bank Of Canada upped their price objective on shares of Intercept Pharmaceuticals from $200.00 to $244.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 26th. Cowen and Company reaffirmed a “buy” rating and set a $112.00 price objective on shares of Intercept Pharmaceuticals in a research report on Wednesday. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Intercept Pharmaceuticals in a research report on Tuesday, September 26th.

In related news, CEO Mark Pruzanski sold 1,532 shares of the stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $58.87, for a total value of $90,188.84. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Lisa Bright sold 253 shares of the stock in a transaction on Friday, August 25th. The stock was sold at an average price of $111.31, for a total value of $28,161.43. Following the completion of the transaction, the insider now owns 23,324 shares in the company, valued at $2,596,194.44. The disclosure for this sale can be found here. Insiders have sold a total of 4,069 shares of company stock worth $325,974 over the last 90 days. Company insiders own 9.20% of the company’s stock.

Institutional investors and hedge funds have recently modified their holdings of the stock. Sphera Funds Management LTD. lifted its holdings in shares of Intercept Pharmaceuticals by 100.0% in the 2nd quarter. Sphera Funds Management LTD. now owns 30,000 shares of the biopharmaceutical company’s stock worth $3,632,000 after purchasing an additional 15,000 shares in the last quarter. Vanguard Group Inc. lifted its stake in Intercept Pharmaceuticals by 4.5% during the 2nd quarter. Vanguard Group Inc. now owns 1,328,133 shares of the biopharmaceutical company’s stock valued at $160,797,000 after acquiring an additional 57,149 shares in the last quarter. Oppenheimer & Co. Inc. lifted its stake in Intercept Pharmaceuticals by 9.0% during the 1st quarter. Oppenheimer & Co. Inc. now owns 2,152 shares of the biopharmaceutical company’s stock valued at $244,000 after acquiring an additional 178 shares in the last quarter. Dynamic Technology Lab Private Ltd lifted its stake in Intercept Pharmaceuticals by 85.6% during the 2nd quarter. Dynamic Technology Lab Private Ltd now owns 6,798 shares of the biopharmaceutical company’s stock valued at $824,000 after acquiring an additional 3,136 shares in the last quarter. Finally, Geode Capital Management LLC lifted its stake in Intercept Pharmaceuticals by 12.8% during the 1st quarter. Geode Capital Management LLC now owns 144,130 shares of the biopharmaceutical company’s stock valued at $16,301,000 after acquiring an additional 16,392 shares in the last quarter. Institutional investors own 82.81% of the company’s stock.

Shares of Intercept Pharmaceuticals (NASDAQ ICPT) traded up $0.23 during trading on Wednesday, hitting $65.09. 1,002,200 shares of the stock were exchanged, compared to its average volume of 1,186,875. The company has a debt-to-equity ratio of 2.05, a current ratio of 6.61 and a quick ratio of 6.61.

Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($2.89) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($3.48) by $0.59. Intercept Pharmaceuticals had a negative net margin of 344.74% and a negative return on equity of 152.78%. The company had revenue of $41.33 million during the quarter, compared to analysts’ expectations of $36.95 million. During the same quarter in the previous year, the business posted ($3.59) earnings per share. Intercept Pharmaceuticals’s quarterly revenue was up 697.9% on a year-over-year basis. sell-side analysts forecast that Intercept Pharmaceuticals will post -13.79 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Intercept Pharmaceuticals, Inc. (ICPT) Receives $136.04 Average Price Target from Brokerages” was published by Watch List News and is owned by of Watch List News. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.watchlistnews.com/intercept-pharmaceuticals-inc-icpt-receives-136-04-average-price-target-from-brokerages/1678795.html.

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.